Table 2.
Mean percentage change (standard error) in bone mineral density over 5 years in continuation versus discontinuation of bisphosphonate groups
| Trial | Continuation/discontinuation | Lumbar spine | Femoral neck | Trochanter |
|---|---|---|---|---|
| Alendronate | ||||
| Black et al17 (FLEX) | Continuation | 5.26 (0.24) | 0.46 (0.24) | −0.08 (0.22) |
| Discontinuation | 1.52 (0.29) | −1.48 (0.30) | −3.25 (0.27) | |
| Alendronate | ||||
| Bone et al19,a | Continuation | |||
| 5 mg group | 2.5 (0.56) | 1.0 (0.87) | 0.0 (0.87) | |
| 10 mg group | 3.7 (0.56) | 0.9 (0.87) | 1.0 (0.82) | |
| Discontinuation | 0.3 (0.61) | −2.2 (0.87) | −1.0 (0.82) | |
| Etidronate | ||||
| Miller et al18,b | Continuation | 1.8 (0.71) | 0.5 (0.82) | 0.4 (0.76) |
| Discontinuation | 1.4 (1.11) | –0.9 (0.96) | –0.6 (0.91) |
Notes:
a
No combined continuation group data available. Standard error calculated from confidence intervals provided in paper;
b
Results are from 2-year follow-up.